WAY-100635 (maleate)

WAY-100635 maleate is a potent and selective 5-hydroxytryptamine 1A (5-HT1A) receptor antagonist with an IC50 value of 0.91 nM and Ki value of 0.39 nM. WAY-100635 maleate has pIC50 values for 5-HT1A and α1-adrenergic receptors of 8.9 and 6.6, respectively. WAY-100635 maleate is also a potent dopamine D4 receptor agonist[1][2][3].

Product Specifications

CAS Number

[1092679-51-0]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

5-HT Receptor; Dopamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/WAY-100635_Maleate.html

Purity

99.89

Solubility

DMSO : ≥ 250 mg/mL|H2O : 25 mg/mL (ultrasonic)

Smiles

OC(/C=C\C(O)=O)=O.COC1=C(N2CCN(CC2)CCN(C3=CC=CC=N3)C(C4CCCCC4)=O)C=CC=C1

Molecular Formula

C29H38N4O6

Molecular Weight

538.64

Precautions

H302, H315, H319, H335

References & Citations

[1]Chemel BR, et al. WAY-100635 is a potent dopamine D4 receptor agonist. Psychopharmacology (Berl) . 2006 Oct;188 (2) :244-51.|[2]Mannucci C, et al. Serotonin involvement in Rhodiola rosea attenuation of nicotine withdrawal signs in rats. Phytomedicine. 2012 Sep 15;19 (12) :1117-24.|[3]Al Hussainy R, et al. Design, synthesis, radiolabeling, and in vitro and in vivo evaluation of bridgehead iodinatedanalogues of N-{2-[4- (2-methoxyphenyl) piperazin-1-yl]ethyl}-N- (pyridin-2-yl) cyclohexanecarboxamide (WAY-100635) as potential SPECT ligands for the 5-HT1A receptor. J Med Chem. 2011 May 26;54 (10) :3480-91.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

5-HT1 Receptor; D4 Receptor

Citation 01

Psychopharmacology (Berl) . 2022 Nov;239 (11) :3551-3565.|Psychopharmacology (Berl) . 2024 Nov;241 (11) :2315-2330.|Biomedicines. 2025 Sep 23;13 (10) :2319.|Chin J Integr Med. 2021 Jul;27 (7) :534-541.|Chin Med. 2024 Jun 15;19 (1) :87.|Int Immunopharmacol. 2024 Feb 15:128:111524.|iScience. 2025 Nov 25;28 (12) :114211.|Nat Neurosci. 2022 Jan;25 (1) :39-49.